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Aims. Several treatments have been proposed to slow down progression of Retinitis pigmentosa (RP), a hereditary retinal
degenerative condition leading to severe visual impairment.The aim of this study is to systematically review data from randomized
clinical trials (RCTs) evaluating safety and efficacy of medical interventions for the treatment of RP.Methods. Randomized clinical
trials on medical treatments for syndromic and nonsyndromic RP published up to December 2014 were included in the review.
Visual acuity, visual field, electroretinogram, and adverse events were used as outcome measures. Results. The 19 RCTs included
in this systematic review included trials on hyperbaric oxygen delivery, topical brimonidine tartrate, vitamins, docosahexaenoic
acid, gangliosides, lutein, oral nilvadipine, ciliary neurotrophic factor, and valproic acid. All treatments proved safe but did not
show significant benefit on visual function. Long term supplementation with vitamin A showed a significantly slower decline rate
in electroretinogram amplitude. Conclusions.Although all medical treatments for RP appear safe, evidence emerging from RCTs is
limited since they do not present comparable results suitable for quantitative statistical analysis. The limited number of RCTs, the
poor clinical results, and the heterogeneity among studies negatively influence the strength of recommendations for the long term
management of RP patients.
1. Introduction
Retinitis pigmentosa (RP) comprises a group of inherited
progressive retinal dystrophies, characterized by rod and
cone photoreceptor degeneration and progressive loss of
peripheral and central vision. Retinitis pigmentosa is often
diagnosed in children and young adults and, as the disease
progresses and more photoreceptors degenerate, patients
experience centripetal visual loss leading to legal and func-
tional blindness [1–3].
Due to the progressive nature of the disease, there is
great interest in the development of therapeutic interventions
that may halt the evolution of the disease or restore the
lost visual function. Currently, the therapeutic approach is
restricted to slowing down the degenerative process, treating
the ocular complications such as cataract andmacular edema,
and helping patients to copewith the social and psychological
impact of blindness [1].
Nonpharmacological interventions are based on strate-
gies of light protection as evidences indicate that some genetic
types of pigmentary retinopathies are partly light-dependent
[4]. Hyperbaric oxygen therapy has been also proposed for
RP patients in order to promote photoreceptors survival [5,
6].
Several medical treatments have been proposed to slow
down disease progression. Specifically, the trophic and
antioxidant effects of vitamins have been evaluated in RP
patients in order to demonstrate a protective action on
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photoreceptors [1, 7, 8]. Other nutritional supplementations,
including docosahexaenoic acid (DHA), an omega 3 fatty
acid found in high concentration in oil fish, lutein, and
gangliosides are cited as a potential therapeutic modality that
can help in preserving the visual function of patients with
RP. Among them, DHA is considered important for photore-
ceptor function because membranes containing rhodopsin
and cone opsins in photoreceptor cells have very high
concentrations of this fatty acid, while the protective effect of
lutein supplementation has been demonstrated in age-related
macular degeneration [9, 10].
Other pharmacological treatments have been proposed
for RP in small clinical studies, including oral valproic acid,
oral nilvadipine, and beta-carotene [11–13]. Lastly, topical
brimonidine tartrate 0.2% treatment and intravitreal delivery
of ciliary neurotrophic factor (CNTF)were proposed for their
neuroprotective effects observed in animal studies [14, 15].
The objective of this study was to systematically review
scientific evidence currently available in the literature, in
order to assess the effects of medical interventions for the
treatment of patients with RP. All the randomized clinical
trials for the evaluation of any medical treatments for RP
published up to December 2014 were included in the review.
2. Materials and Methods
2.1. Literature Search. Six observers, divided in three groups
of two, independently performed a literature search of all
publication years up to December 2014. The articles were
identified through a computerized search for clinical trials in
the Cochrane Controlled Trial Register (CENTRAL/CCTR)
(which contains the Cochrane Eyes and vision group trials
register) on the Cochrane Library, Medline, and Embase.
The search strategy was used to identify randomized clinical
trials, as recommended by the Cochrane collaboration.
The following search strategy was used:
(a) Publication type was clinical trial.
(b) Keywords/search terms for disease were as follows:
pigmentosa and retiniti∗, explode retinitis pigmen-
tosa/all subheadings, RP/all subheadings, pigment∗
and retin∗, and explode pigmentary retinopathy/all
subheadings.
(c) Keywords/search terms for medications were as fol-
lows: vit∗, explode vitamin A and/or vitamin E/all
subheadings, retinol, retinyl palmitate, tocopherol,
tocotrienol, lutein, carotenoid, omega 3/all subhead-
ings, fatty acid/all subheadings, docosahexaenoic acid,
DHA, cervonic acid, eicosapentaenoic acid, EPA,
alpha-linolenic acid, ALA, alpha-2 agonist, alpha-
2 adrenergic, brimonidine, clonidine, apraclonidine,
ganglioside, valproic acid, nilvadipine, hyperbar∗,
explode hyperbaric/all subheadings, neurotrophin,
and neurotrophic factor.
In addition, linked references in all relevant articles were
searched. The search resulted in a total of 389 abstracts.
2.2. Inclusion and Exclusion Criteria
2.2.1. Type of Studies. Articles potentially eligible for inclu-
sion in this systematic review were randomized clinical trials
on medical therapy for RP with at least 4 weeks of follow-up
published up to December 2014, written in English, French,
German, Italian, Portuguese, or Spanish.
2.2.2. Type of Participants. All participants who have been
diagnosed with RP were included with no restrictions of age,
gender, ethnicity, or use of adjunctive therapy. Trials evaluat-
ing patients with ocular comorbidities or complications that
are known to influence visual function were excluded.
2.2.3. Type of Interventions. Studies that specifically inves-
tigated the experimental medical interventions for RP such
as vitamin A, vitamin E, omega 3 fatty acids (DHA), lutein,
alpha-2 agonists, gangliosides, nilvadipine, valproic acid,
CNTF, hyperbaric oxygen delivery (HBO), and light protec-
tion were included.
2.2.4. Types of Comparisons. Anymedical cointerventionwas
considered.
Articles were excluded if they did not satisfy one or more
inclusion criteria or if theywere irretrievable after performing
all available search strategies, including request to authors
and editors.
The articles’ eligibility was initially determined by eval-
uating the titles, abstracts, and MeSH (medical subject
headings). Four observers divided into two groups of two
examined all the retrieved 389 abstracts to consider their
eligibility. Aftermatching the decisions of the two groups, 360
abstractswere immediately excluded because theywere either
not randomized, not on medical treatment for RP, or related
to different kinds of ocular disease. The remaining 29 com-
plete articles were obtained and printed to identify whether
theywere suitable for inclusion in the revision and distributed
to four researchers randomly divided into two groups of two
each.The observers were blinded to the names of the authors
and institutions, the name of the journals, the sources of
funding, and the sponsors of the studies. The observers of
each group were also blinded to the decisions of the other
group and trial selection was matched between them. Nine
trials were excluded because they did not match one or more
inclusion criteria and one was excluded because it was not
eligible [16–25]. All the remaining 19 RCTs were included in
the systematic review [5, 6, 8–11, 13–15, 17, 26–34] (Figure 1).
2.3. Outcome Measures. Outcome measures included in this
review are changes in visual field (Goldmann perimeter and
Humprey visual field analyzer), best corrected visual acuity
(BCVA), electroretinogram (ERG) amplitude, contrast sensi-
tivity, dark adaptation, and treatment-related adverse events.
2.4. Assessment of Risk of Bias in Included Studies
Validity Assessment. Two authors independently assessed the
included studies for sources of systematic bias according to
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Figure 1: Decision tree of randomized clinical trials’ selection for
inclusion in the systematic review and meta-analysis.
the guidelines in section 6 of the Cochrane handbook for
systematic reviews of interventions. Specifically, the following
criteria were considered.
All studies included in the review were randomised con-
trolled trials. The main quality attributes were scored as “low
risk,” “high risk,” and “unclear risk” for the following areas:
(i) whether or not the randomisation is properly concealed
(random sequence generation and allocation concealment),
(ii) whether or not the participants are masked (blinding),
(iii) whether or not the outcome assessment is masked
(incomplete outcome data), and (iv) for selective reporting
bias. Other biases include the presence of commercial sup-
port, potential source of bias related to the specific study
design used, or we are not sure whether an important risk of
bias existed (Figure 2).
Data Synthesis.We were unable to conduct meta-analyses on
RP treatments because of the clinical heterogeneity observed
between studies.Different interventions, different time points
for outcome measures, and different instruments and meth-
ods of outcome evaluation meant that a summary effect was
not estimated.
2.5. Statistical Analysis. RevMan5 software was used to anal-
yse the data. We tested the heterogeneity between studies
using the Chi-square test, with significant heterogeneity (𝑝 <
0.05) precluding meta-analysis.
3. Results
The 19 studies included in the systematic review dated from
1968 to 2014, all but one of these published in ophthalmic
journals. Two trials were performed in Europe, 4 in Asia, and
13 in America. All were randomized clinical trials. Sixteen
studies were double-masked or single- (investigator-)masked
and three were unmasked (Table 1). RCTs included in this
systematic review lasted from 4 months to 10 years with a
mean duration of approximately three and a half years.
A total of 1774 patients with RP were enrolled in these
studies. Demographic characteristics are summarized in
Table 2. The 19 studies included in this systematic review
evaluated the following interventions in RP patients: two
on HBO [5, 6], one on topical brimonidine tartrate [14],
five on vitamins supplementation [8, 26–28, 33], 4 on DHA
supplementation [29–31, 34], 2 trials on lutein [9, 10], one on
gangliosides’ supplementation [32], one on nilvadipine [13],
one on beta-carotene [11], one on CNTF [15], and one on oral
valproic acid [12]. Results of the RCTs included in this review
are summarized in Table 3.
While in some trials randomization appeared to have
been executed properly, that is, an unpredictable sequence of
treatment allocation was concealed adequately from people
recruiting participants into the trial, the following biases have
arisen in the trials included in this review (Figure 2):
(i) Sequence generation was not specified or performed
in seven studies [5, 6, 13–15, 28, 33].
(ii) Allocation concealment was not specified or per-
formed in five trials [5, 6, 13, 28, 33].
(iii) Five studies were unmasked [5, 6, 12, 13, 33].
3.1. Effects of Interventions on the Progression of RP
3.1.1. Vitamin A Supplementation. Vitamin A supplemen-
tation did not show significant benefit on visual acuity,
Goldman visual field, and dark adaptometry as compared to
placebo in a first study by Chatzinoff et al. that evaluated 89
patients with RP for 3 years [28]. Later studies comparing
vitamin A (15000 IU/day) and E (400UI/day) versus placebo
(traces amount of both vitamins) in a population of 601
patients with RP followed for 4 to 6 years reported that the
groups receiving vitamin A showed a significantly slower rate
of decline of ERG amplitude, which was not observed in
patients receiving only traces amount of vitamins (placebo).
The groups receiving vitamin A were 32% less likely to have a
decline in ERG amplitude from baseline in a given year. Data
from this study also showed that patients receiving vitamin E
(400UI/day) showed a greater loss of retinal functions than
placebo groups [33, 35].
3.1.2. Docosahexaenoic Acid (DHA) Supplementation. In a 4-
year RCTbyHoffman et al., DHA (400mg/die) treatmentwas
not effective in improving visual acuity, visual field, ERG, and
dark adaptometry when compared to placebo. In the same
study population, Wheaton et al. reported that four-year
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Ta
bl
e
1:
St
ud
y
de
sig
n
an
d
ch
ar
ac
te
ris
tic
so
fr
an
do
m
iz
ed
cli
ni
ca
lt
ria
ls
in
clu
de
d
in
th
es
ys
te
m
at
ic
re
vi
ew
.
Ra
nd
om
iz
ed
cli
ni
ca
lt
ria
l
M
as
ki
ng
Tr
ea
tm
en
ts
Tr
ea
tm
en
td
ur
at
io
n
Ti
m
e-
po
in
te
va
lu
at
io
n
Ch
at
zi
no
ff
et
al
.1
96
8
[2
8]
D
ou
bl
e-
m
as
ke
d,
co
nt
ro
lle
d
10
0.
00
0U
11-
ci
sv
ita
m
in
A
IM
tw
ic
ew
ee
kl
y
ve
rs
us
10
0.
00
0
al
l-t
ra
ns
vi
ta
m
in
A
IM
tw
ic
ew
ee
kl
y
3
ye
ar
s
Ev
er
y
six
m
on
th
sf
or
th
e
du
ra
tio
n
of
th
es
tu
dy
N
ew
so
m
ee
ta
l.
19
87
[3
2]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d
G
an
gl
io
sid
es
40
m
g/
2m
L/
da
y
IM
ve
rs
us
0.
9%
so
di
um
ch
lo
rid
e
so
lu
tio
n/
da
y
IM
in
je
ct
io
n
4
m
on
th
s
Ba
se
lin
e,
4
m
on
th
s.
Be
rs
on
et
al
.1
99
3
[8
]
D
ou
bl
e-
m
as
ke
d
tr
ia
l
w
ith
2
×
2
fa
ct
or
ia
l
de
sig
n
Vi
ta
m
in
A
15
,0
00
IU
/d
ay
+
vi
ta
m
in
E
3U
I/d
ay
(g
rA
),
vi
ta
m
in
A
75
IU
/d
ay
+
vi
ta
m
in
E
40
0I
U
/d
ay
(g
rE
),
or
vi
ta
m
in
A
15
,0
00
IU
/d
ay
+
vi
ta
m
in
E
40
0I
U
/d
ay
(g
rA
+
E)
ve
rs
us
tr
ac
e
am
ou
nt
so
fb
ot
h
vi
ta
m
in
A
(7
5I
U
/d
ay
)a
nd
vi
ta
m
in
E
(3
U
I/d
ay
)
(tr
ac
eg
ro
up
)
4
to
6
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
Si
bu
le
sk
y
et
al
.1
99
9
[3
3]
Lo
ng
te
rm
sa
fe
ty
in
th
es
am
e
po
pu
la
tio
n
of
Be
rs
on
et
al
.1
99
3
[8
]
D
ou
bl
e-
m
as
ke
d
Vi
ta
m
in
A
15
,0
00
IU
/d
ay
+
vi
ta
m
in
E
3U
I/d
ay
(g
rA
),
vi
ta
m
in
A
75
IU
/d
ay
+
vi
ta
m
in
E
40
0I
U
/d
ay
(g
rE
),
or
vi
ta
m
in
A
15
,0
00
IU
/d
ay
+
vi
ta
m
in
E
40
0I
U
/d
ay
(g
rA
+
E)
ve
rs
us
tr
ac
e
am
ou
nt
so
fb
ot
h
vi
ta
m
in
A
(7
5I
U
/d
ay
)a
nd
vi
ta
m
in
E
(3
U
I/d
ay
)
(tr
ac
eg
ro
up
)
U
p
to
12
ye
ar
s
Ba
se
lin
e,
5
an
d
12
ye
ar
s
Vi
ng
ol
o
et
al
.1
99
8
[6
]
U
nm
as
ke
d
stu
dy
H
yp
er
ba
ric
ox
yg
en
90
m
in
O
2
da
ily
5
tim
es
aw
ee
k
fo
r1
m
on
th
,1
w
ee
k
am
on
th
fo
r1
1m
on
th
s,
an
d
1w
ee
k
ev
er
y
3
m
on
th
sf
or
2
ye
ar
s
ve
rs
us
no
hy
pe
rb
ar
ic
ox
yg
en
3
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
W
he
at
on
et
al
.2
00
3
[3
4]
Lo
ng
te
rm
sa
fe
ty
in
th
es
am
e
po
pu
la
tio
n
of
H
off
m
an
et
al
.2
00
4
[3
0]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d
O
ra
lD
H
A
40
0m
g/
da
y
su
pp
le
m
en
ta
tio
n
ve
rs
us
pl
ac
eb
o
4
ye
ar
s
Ev
er
y
6
m
on
th
sf
or
th
e
du
ra
tio
n
of
th
es
tu
dy
Be
rs
on
et
al
.2
00
4
[2
7]
D
ou
bl
e-
m
as
ke
d,
co
nt
ro
lle
d
Fa
tty
ac
id
sw
ith
D
H
A
12
00
m
g/
da
y
+
vi
ta
m
in
A
15
00
0U
I/d
ay
ve
rs
us
fa
tty
ac
id
s+
vi
ta
m
in
A
15
00
0U
I/d
ay
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
Be
rs
on
et
al
.2
00
4
[2
6]
Su
bg
ro
up
an
al
ys
is
of
Be
rs
on
et
al
.
20
04
[2
7]
:p
at
ie
nt
st
ak
in
g
vi
ta
m
in
A
pr
io
rt
o
en
tr
y
ve
rs
us
pa
tie
nt
sn
ot
ta
ki
ng
vi
ta
m
in
A
pr
io
rt
o
en
tr
y
D
ou
bl
e-
m
as
ke
d,
co
nt
ro
lle
d
Fa
tty
ac
id
sw
ith
D
H
A
12
00
m
g/
da
y
+
vi
ta
m
in
A
15
00
0U
I/d
ay
ve
rs
us
fa
tty
ac
id
s+
vi
ta
m
in
A
15
00
0U
I/d
ay
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
H
off
m
an
et
al
.2
00
4
[3
0]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d
O
ra
lD
H
A
40
0m
g/
da
y
su
pp
le
m
en
ta
tio
n
ve
rs
us
pl
ac
eb
o
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
Ba
hr
am
ie
ta
l.
20
06
[9
]
D
ou
bl
e-
m
as
ke
d,
cr
os
so
ve
r
Lu
te
in
ca
ps
ul
e1
0m
g/
da
y
fo
r1
2
w
ee
ks
an
d
th
en
30
m
g/
da
y
fo
r1
2
w
ee
ks
+
m
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
ve
rs
us
pl
ac
eb
o
ca
ps
ul
e+
m
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
6
m
on
th
s
Ba
se
lin
e,
6,
12
,1
8,
an
d
24
w
ee
ks
M
er
in
et
al
.2
00
8
[14
]
D
ou
bl
em
as
ke
d,
co
nt
ro
lle
d
Br
im
on
id
in
et
ar
tr
at
e0
.2
%
ey
ed
ro
ps
BI
D
ve
rs
us
ar
tifi
ci
al
te
ar
sB
ID
2-
3
ye
ar
s(
m
ea
n:
29
.3
m
on
th
s)
Ev
er
y
6–
8
m
on
th
sf
or
th
ed
ur
at
io
n
of
th
es
tu
dy
Vi
ng
ol
o
et
al
.2
00
8
[5
]
U
nm
as
ke
d,
co
nt
ro
lle
d
H
yp
er
ba
ric
ox
yg
en
90
m
in
O
2
da
ily
5
da
ys
aw
ee
k
fo
r1
m
on
th
,5
co
ns
ec
ut
iv
ed
ay
sa
m
on
th
fo
r1
1m
on
th
s,
an
d
5
co
ns
ec
ut
iv
ed
ay
s
ev
er
y
3
m
on
th
sf
or
9
ye
ar
sv
er
su
sv
ita
m
in
A
10
ye
ar
s
Ev
er
y
6
m
on
th
sf
or
th
e
du
ra
tio
n
of
th
es
tu
dy
Be
rs
on
et
al
.2
01
0
[1
0]
D
ou
bl
em
as
ke
d,
co
nt
ro
lle
d
12
m
g
or
al
lu
te
in
+
vi
ta
m
in
A
15
00
0U
I/d
ay
ve
rs
us
pl
ac
eb
o
+
vi
ta
m
in
A
15
00
0U
I/d
ay
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
N
ak
az
aw
ae
ta
l.
20
11
[1
3]
N
on
m
as
ke
d
O
ra
ln
ilv
ad
ip
in
e4
m
g/
da
y
ve
rs
us
to
co
ph
er
ol
ni
co
tin
at
e
30
0m
g/
da
y
or
he
le
ni
en
15
m
g/
da
y
or
no
tre
at
m
en
ts
30
–6
6
m
on
th
s
Ev
er
y
6
m
on
th
sf
or
th
e
du
ra
tio
n
of
th
es
tu
dy
Journal of Ophthalmology 5
Ta
bl
e
1:
C
on
tin
ue
d.
Ra
nd
om
iz
ed
cli
ni
ca
lt
ria
l
M
as
ki
ng
Tr
ea
tm
en
ts
Tr
ea
tm
en
td
ur
at
io
n
Ti
m
e-
po
in
te
va
lu
at
io
n
Ro
te
ns
tre
ic
h
et
al
.2
01
3
[1
1]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r
Fo
ur
ca
ps
ul
e/
da
y
of
9-
ci
s𝛽
-c
ar
ot
en
e-
ric
h
al
ga
D
un
al
iel
la
ba
rd
aw
il
(𝛽
-c
ar
ot
en
e,
ap
pr
ox
im
at
ely
20
m
g)
ve
rs
us
4-
da
y
ca
ps
ul
eo
fp
la
ce
bo
3
m
on
th
so
f
tre
at
m
en
t,
3
m
on
th
s
of
w
as
ho
ut
,3
m
on
th
s
of
cr
os
so
ve
r
Ba
se
lin
e,
aft
er
3
m
on
th
s
of
tre
at
m
en
t,
aft
er
3
m
on
th
so
fw
as
ho
ut
,a
nd
aft
er
3
m
on
th
so
f
cr
os
so
ve
rt
re
at
m
en
t
Bi
rc
h
et
al
.2
01
3
[1
5]
Re
su
lts
of
CN
TF
3
+
CN
TF
4
stu
di
es
M
as
ke
d,
ra
nd
om
iz
ed
,
sh
am
-c
on
tro
lle
d
H
ig
h
(2
0n
g/
da
y)
or
lo
w
(5
ng
/d
ay
)d
os
ec
ili
ar
y
ne
ur
ot
ro
ph
ic
fa
ct
or
in
tr
ao
cu
la
ri
m
pl
an
tv
er
su
ss
ha
m
in
tr
ao
cu
la
ri
m
pl
an
ti
n
th
ef
el
lo
w
ey
e
1(
CN
TF
3)
or
2
ye
ar
s
(C
N
TF
4)
1d
ay
,1
w
ee
k,
1,
3,
12
,a
nd
24
m
on
th
s,
an
d
fo
llo
w
-u
p
up
to
42
m
on
th
s
H
off
m
an
et
al
.2
01
4
[2
9]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d
M
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
+
D
H
A
30
m
g/
kg
/d
ay
ve
rs
us
m
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
+
pl
ac
eb
o
ca
ps
ul
es
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
H
ug
hb
an
ks
-W
he
at
on
et
al
.2
01
4
[3
1]
Sa
m
ep
op
ul
at
io
n
of
H
off
m
an
et
al
.
20
14
[2
9]
D
ou
bl
e-
m
as
ke
d,
pl
ac
eb
o-
co
nt
ro
lle
d
M
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
+
D
H
A
30
m
g/
kg
/d
ay
ve
rs
us
m
ul
tiv
ita
m
in
su
pp
le
m
en
ta
tio
n
+
pl
ac
eb
o
ca
ps
ul
es
4
ye
ar
s
Ea
ch
ye
ar
fo
rt
he
du
ra
tio
n
of
th
es
tu
dy
Ku
m
ar
et
al
.2
01
4
[1
2]
D
at
ae
va
lu
at
or
s,
m
as
ke
d
O
ra
lv
al
pr
oi
ca
ci
d
50
0m
g/
da
y
ve
rs
us
no
tre
at
m
en
t
1y
ea
r
Ba
se
lin
e,
3,
6,
an
d
12
m
on
th
s
BI
D
:T
w
ic
ed
ai
ly.
Q
D
:O
nc
ea
da
y.
Q
ID
:F
ou
rt
im
es
da
ily
.
6 Journal of Ophthalmology
Ta
bl
e
2:
Ch
ar
ac
te
ris
tic
so
fs
tu
dy
po
pu
lat
io
n
in
th
er
an
do
m
iz
ed
cli
ni
ca
lt
ria
ls
in
clu
de
d
in
th
es
ys
te
m
at
ic
re
vi
ew
.
Ra
nd
om
iz
ed
cli
ni
ca
lt
ria
l
(c
ou
nt
ry
)
Po
pu
la
tio
n
N
um
be
ro
fp
at
ie
nt
sr
an
do
m
iz
ed
pe
r
gr
ou
p
(e
xp
er
im
en
ta
l/c
on
tro
l)
M
ea
n
ag
eo
fp
at
ie
nt
sp
er
gr
ou
p
(y
ea
rs
)(
ex
pe
rim
en
ta
l/c
on
tro
l)
G
en
de
rp
er
gr
ou
p
(e
xp
er
im
en
ta
l/c
on
tro
l)
Ch
at
zi
no
ff
et
al
.1
96
8
(U
SA
)[
28
]
71
pa
tie
nt
sw
ith
RP
36
/3
5
N
A
N
A
N
ew
so
m
ee
ta
l.
19
87
(U
SA
)[
32
]
32
pa
tie
nt
sw
ith
RP
17
/15
43
.7
/3
9.8
10
M
,7
F/
13
M
,2
F
Be
rs
on
et
al
.1
99
3
[8
](
U
SA
)
60
1p
at
ie
nt
sw
ith
ty
pi
ca
lR
P
G
ro
up
A
=
14
6,
gr
ou
p
E
=
15
5,
gr
ou
p
A
+
E
=
15
1,
tr
ac
eg
ro
up
=
14
9
G
ro
up
A
=
32
.5
,g
ro
up
E
=
31
.5
,g
ro
up
A
+
E
=
32
.3
,t
ra
ce
gr
ou
p
=
32
.2
37
3M
,2
28
F
Si
bu
le
sk
y
et
al
.1
99
9
[3
3]
(U
SA
)
12
1p
at
ie
nt
sw
ith
ty
pi
ca
lR
P
G
ro
up
A
=
11
5,
tr
ac
eg
ro
up
=
10
6
N
A
N
A
Vi
ng
ol
o
et
al
.1
99
8
[6
](
IT
A
)
48
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
24
/2
4
33
.6
/3
2.
8
14
M
,1
0F
/16
M
,8
F
W
he
at
on
et
al
.2
00
3
[3
4]
an
d
H
off
m
an
et
al
.2
00
4
[3
0]
(U
SA
)
44
X-
lin
ke
d
RP
pa
tie
nt
s
23
/2
1
14
.9
/18
23
M
/2
1M
Be
rs
on
et
al
.2
00
4
(U
SA
)[
27
]
20
8
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
10
5/
10
3
37
.8
/3
6
50
M
,5
5F
/5
6M
,4
7F
Be
rs
on
et
al
.2
00
4a
∗
(U
SA
)[
26
]
Su
bg
ro
up
an
al
ys
is
of
Be
rs
on
et
al
.
20
04
[2
7]
20
8
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
Vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
75
/6
8
N
o
vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
30
/3
5
Vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
38
.1/
36
.8
N
o
vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
36
.9
/3
4.
5
Vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
37
F,
38
M
/3
2F
,3
8M
N
o
vi
ta
m
in
A
pr
io
rt
o
en
tr
y:
18
F,
12
M
/17
F,
18
M
Ba
hr
am
ie
ta
l.
20
06
[9
](
U
SA
)
34
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
16
/18
cr
os
so
ve
rd
es
ig
n
52
.4
/4
6.
4
11
F,
5M
/10
F,
8M
M
er
in
et
al
.2
00
8
[14
](
Is
ra
el
)
17
pa
tie
nt
sw
ith
RP
17
pa
tie
nt
sr
an
do
m
iz
ed
pe
re
ye
38
10
M
,7
F
Vi
ng
ol
o
et
al
.2
00
8
[5
](
IT
A
)
88
pa
tie
nt
sw
ith
RP
44
/4
4
35
/3
5.
5
21
M
,2
3F
/2
1M
,2
3F
Be
rs
on
et
al
.2
01
0
[1
0]
(U
SA
)
22
5
no
ns
m
ok
er
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
11
0/
11
5
40
/3
8
58
M
,4
2F
/5
2M
,6
3F
N
ak
az
aw
ae
ta
l.
20
11
[1
3]
(Ja
pa
n)
33
pa
tie
nt
sw
ith
RP
19
/14
52
/4
8
9M
,1
0F
/7
M
,7
F
Ro
te
ns
tre
ic
h
et
al
.2
01
3
[1
1]
(Is
ra
el
)
29
pa
tie
nt
sw
ith
RP
16
D
un
al
iel
la
-fi
rs
tg
ro
up
/18
pl
ac
eb
o-
fir
st
gr
ou
p
46
.7
21
M
,8
F
Bi
rc
h
et
al
.2
01
3
[1
5]
(U
SA
)
65
pa
tie
nt
sw
ith
la
te
-s
ta
ge
RP
(C
N
TF
3
stu
dy
),
an
d
68
pa
tie
nt
s
w
ith
ea
rly
-s
ta
ge
RP
(C
N
TF
4
stu
dy
)
Lo
w
do
se
:4
2
H
ig
h
do
se
:9
1
Sh
am
:1
33
(fe
llo
w
ey
e)
Lo
w
do
se
:3
8
H
ig
h
do
se
:4
1
Lo
w
do
se
:2
4M
,1
8F
H
ig
h
do
se
:4
3M
,4
8F
H
off
m
an
et
al
.2
01
4
[2
9]
(U
SA
)
an
d
H
ug
hb
an
ks
-W
he
at
on
et
al
.
20
14
[3
1]
60
X-
lin
ke
d
RP
pa
tie
nt
s
27
/3
3
16
.1/
14
.9
27
M
/3
3M
Ku
m
ar
et
al
.2
01
4
[1
2]
(In
di
a)
30
pa
tie
nt
sw
ith
ty
pi
ca
lR
P
15
/15
30
/3
1
10
M
,5
F/
12
M
,3
F
RP
:R
et
in
iti
sp
ig
m
en
to
sa
.
CN
TF
:C
ili
ar
y
ne
ur
ot
ro
ph
ic
fa
ct
or
.
M
:M
al
e.
F:
Fe
m
al
e.
∗
Su
bg
ro
up
an
al
ys
is
of
Be
rs
on
20
04
stu
dy
:p
at
ie
nt
st
ak
in
g
vi
ta
m
in
A
pr
io
rt
o
en
tr
y
ve
rs
us
pa
tie
nt
sn
ot
ta
ki
ng
vi
ta
m
in
A
pr
io
rt
o
en
tr
y.
Journal of Ophthalmology 7
Ta
bl
e
3:
Su
m
m
ar
y
of
re
su
lts
of
th
er
an
do
m
iz
ed
cli
ni
ca
lt
ria
ls
in
clu
de
d
in
th
es
ys
te
m
at
ic
re
vi
ew
.
St
ud
y
BC
VA
Vi
su
al
fie
ld
C
on
tr
as
t
se
ns
iti
vi
ty
ER
G
D
ar
k
ad
ap
to
m
et
ry
N
um
be
ro
fa
dv
er
se
ev
en
ts
pe
r
gr
ou
p
(e
xp
er
im
en
ta
l/c
on
tro
l)
Ch
at
zi
no
ff
et
al
.1
96
8
[2
8]
N
o
di
ffe
re
nc
es
N
o
di
ffe
re
nc
es
N
A
N
A
N
o
di
ffe
re
nc
es
N
A
N
ew
so
m
ee
ta
l.
19
87
[3
2]
N
A
N
o
di
ffe
re
nc
es
(G
ol
dm
an
pe
rim
et
ry
)
N
A
N
ot
re
co
rd
ab
le
in
m
os
tp
at
ie
nt
s
N
A
3
m
in
or
A
Es
Be
rs
on
et
al
.1
99
3
[8
]
an
d
Si
bu
le
sk
y
et
al
.
19
99
[3
3]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
N
o
di
ffe
re
nc
es
(G
ol
dm
an
pe
rim
et
ry
)
N
A
Sl
ow
er
ra
te
of
de
cli
ne
in
vi
ta
m
in
A
an
d
vi
ta
m
in
A
+
E
gr
ou
ps
,f
as
te
r
de
cli
ne
in
vi
ta
m
in
E
gr
ou
p
(3
0H
z
ER
G
)
N
A
4
se
ve
re
A
Es
(to
ta
l),
no
di
ffe
re
nc
es
be
tw
ee
n
gr
ou
ps
in
m
in
or
an
d
se
ve
re
A
E
Vi
ng
ol
o
et
al
.1
99
8
[6
]
N
A
N
A
N
A
Im
pr
ov
em
en
ti
n
m
ax
im
al
ER
G
am
pl
itu
de
re
co
rd
ed
w
ith
lo
w
-n
oi
se
m
et
ho
d
in
H
BO
gr
ou
p
N
A
N
A
Be
rs
on
et
al
.2
00
4
[2
7]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
N
o
di
ffe
re
nc
es
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
N
o
di
ffe
re
nc
es
(3
0H
zE
RG
)
N
A
1s
ev
er
eA
E
in
th
ep
la
ce
bo
gr
ou
p
Be
rs
on
et
al
.2
00
4a
[2
6]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
Sl
ow
er
de
cli
ne
in
no
vi
ta
m
in
A
pr
io
rt
o
en
tr
y
+
D
H
A
gr
ou
p
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
Sl
ow
er
de
cli
ne
in
no
vi
ta
m
in
A
pr
io
r
to
en
tr
y
+
D
H
A
gr
ou
p
(3
0H
zE
RG
)
N
A
1s
ev
er
eA
E
in
th
ep
la
ce
bo
gr
ou
p
H
off
m
an
et
al
.2
00
4
[3
0]
an
d
W
he
at
on
et
al
.2
00
3
[3
4]
N
o
di
ffe
re
nc
es
(lo
gM
A
R)
N
o
di
ffe
re
nc
es
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
N
o
di
ffe
re
nc
es
(li
gh
t-a
da
pt
ed
co
ne
31
H
z,
ro
d,
or
m
ax
im
al
ER
G
am
pl
itu
de
s)
N
o
di
ffe
re
nc
es
M
in
or
A
E
in
4
pa
tie
nt
si
n
D
H
A
an
d
6
in
pl
ac
eb
o
gr
ou
ps
.
N
o
se
ve
re
A
E
Ba
hr
am
ie
ta
l.
20
06
[9
]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
Po
sit
iv
ee
ffe
ct
on
pr
es
er
vi
ng
V
F
(G
ol
dm
an
pe
rim
et
ry
)
N
o
di
ffe
re
nc
es
N
A
N
A
M
in
or
A
E,
1/2
M
er
in
et
al
.2
00
8
[14
]
N
o
di
ffe
re
nc
es
(L
og
M
ar
)
N
o
di
ffe
re
nc
es
(G
ol
dm
an
pe
rim
et
ry
)
N
o
di
ffe
re
nc
es
N
A
N
A
N
o
se
ve
re
A
E
A
lle
rg
ic
re
ac
tio
n
in
3
Vi
ng
ol
o
et
al
.2
00
8
[5
]S
lo
w
er
de
cli
ne
in
H
BO
gr
ou
p
(S
ne
lle
n
ch
ar
t)
H
ig
he
rp
er
ce
nt
ag
eo
fs
ta
bi
liz
at
io
n
of
G
ol
dm
an
n
pe
rim
et
ry
-ta
rg
et
I4
an
d
H
FA
10
-2
vi
su
al
fie
ld
si
n
th
eH
BO
gr
ou
p
ve
rs
us
co
nt
ro
lg
ro
up
N
A
St
at
ist
ic
al
ly
sig
ni
fic
an
ti
m
pr
ov
em
en
t
of
ER
G
b-
w
av
ea
m
pl
itu
de
re
co
rd
ed
w
ith
lo
w
-n
oi
se
m
et
ho
d
in
H
BO
gr
ou
p
ve
rs
us
co
nt
ro
ls
N
A
N
A
Be
rs
on
et
al
.2
01
0
[1
0]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
N
o
di
ffe
re
nc
es
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
N
o
di
ffe
re
nc
es
N
ak
az
aw
ae
ta
l.
20
11
[1
3]
N
A
Sl
ow
er
pr
og
re
ss
io
n
of
ce
nt
ra
lV
F
in
tre
at
m
en
tg
ro
up
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
N
A
N
A
N
o
se
ve
re
A
E
Ro
te
ns
tre
ic
h
et
al
.
20
13
[1
1]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
N
o
di
ffe
re
nc
es
in
da
rk
-a
nd
lig
ht
-a
da
pt
ed
V
F
(G
ol
dm
an
n
pe
rim
et
ry
)
N
A
Si
gn
ifi
ca
nt
in
cr
ea
se
of
da
rk
-a
nd
lig
ht
-a
da
pt
ed
ER
G
b-
w
av
ea
m
pl
itu
de
in
tre
at
m
en
tg
ro
up
ve
rs
us
pl
ac
eb
o
N
A
N
o
A
E
Bi
rc
h
et
al
.2
01
3
[1
5]
N
o
di
ffe
re
nc
es
(E
TD
RS
)
N
o
di
ffe
re
nc
es
w
ith
lo
w
do
se
;
sig
ni
fic
an
tw
or
se
ni
ng
in
hi
gh
do
se
ve
rs
us
sh
am
(H
um
ph
re
y
vi
su
al
fie
ld
an
al
yz
er
)
N
A
N
o
di
ffe
re
nc
es
(3
0
H
zfl
ic
ke
ra
nd
sin
gl
e-
fla
sh
ER
G
)
N
A
Lo
w
do
se
:5
oc
ul
ar
A
Es
H
ig
h
do
se
:3
7
oc
ul
ar
A
Es
(2
6
m
io
se
s)
N
o
se
ve
re
A
E
H
off
m
an
et
al
.2
01
4
[2
9]
N
A
N
A
N
A
N
o
di
ffe
re
nc
es
(3
1H
zfl
ic
ke
rE
RG
)
N
A
22
/2
0
TE
A
Es
N
o
se
ve
re
A
E
H
ug
hb
an
ks
-W
he
at
on
et
al
.2
01
4
[3
1]
N
A
N
A
N
A
N
A
N
A
22
/2
0
TE
A
Es
N
o
se
ve
re
A
E
1d
ro
po
ut
du
et
o
ga
str
oi
nt
es
tin
al
sy
m
pt
om
s
Ku
m
ar
et
al
.2
01
4
[1
2]
Si
gn
ifi
ca
nt
im
pr
ov
em
en
ti
n
tre
at
m
en
tg
ro
up
N
A
N
A
Si
gn
ifi
ca
nt
im
pr
ov
em
en
ti
n
tre
at
m
en
tg
ro
up
N
A
3
ga
str
oi
nt
es
tin
al
sy
m
pt
om
s
N
o
se
ve
re
A
E
A
E:
Ad
ve
rs
ee
ve
nt
.
N
A
:N
ot
as
se
ss
ed
.
H
BO
:H
yp
er
ba
ric
ox
yg
en
th
er
ap
y.
8 Journal of Ophthalmology
0 10 20 30 40 50
(%)
60 70 80 90 100
Other biases
Low risk of bias
Unclear risk of bias
High risk of bias
Random sequence generation
(selection bias)
Allocation concealment
(selection bias)
Blinding (performance bias
and detection bias)
Incomplete outcome data
(attrition bias)
Selective reporting
(reporting bias)
(a)
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + + +
+ + + +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + + +
+ + +
+ + +
+
+
+
+
+
+
+
+
+
+
+
+
+ + + + + +
+
+
+
+
++
?
?
?
? ???
Bahrami et al. 2006
Berson et al. 1993
Berson et al. 2004
Berson et al. 2004a
Berson et al. 2010
Birch et al. 2013
Chatzinoff et al. 1968
Hoffman et al. 2004
Hoffman et al. 2014
Hughbanks-Wheaton et al. 2014
Kumar et al. 2014
Merin et al. 2008
Nakazawa et al. 2011
Newsome et al. 1987
Rotenstreich et al. 2013
Sibulesky et al. 1999
Vingolo et al. 1998
Vingolo et al. 2008
Wheaton et al. 2003
−
−
−
−
− −
− − −
− − −
− − −
− − −
−
−
−
O
th
er
 b
ia
se
s
Ra
nd
om
 se
qu
en
ce
 g
en
er
at
io
n
(s
el
ec
tio
n 
bi
as
)
A
llo
ca
tio
n 
co
nc
ea
lm
en
t
(s
el
ec
tio
n 
bi
as
)
Bl
in
di
ng
 (p
er
fo
rm
an
ce
 b
ia
s
an
d 
de
te
ct
io
n 
bi
as
)
In
co
m
pl
et
e o
ut
co
m
e d
at
a
(a
ttr
iti
on
 b
ia
s)
Se
le
ct
iv
e r
ep
or
tin
g
(r
ep
or
tin
g 
bi
as
)
(b)
Figure 2: Risk of bias graph (a) showing authors’ judgements about each risk of bias item presented as percentages across all included studies.
Risk of bias summary (b) reviewing authors’ judgements about each risk of bias item for each included study.
DHA supplementation was associated with an acceptable
safety profile [30, 34]. In a recent study, Hoffman et al.
further evaluated the effects of oral DHA (30mg/kg/day)
supplementation versus placebo in a 4-year study in 78
patients with X-linked RP [29]. The loss rate of cone, rod, or
maximal ERG function was not different between groups. In
the same population, Hughbanks-Wheaton et al. confirmed
the safety profile of long term DHA supplementation in
the same population, with no differences in adverse events
rate, antioxidant activity, platelet aggregation, or plasma
lipoprotein levels between groups [29, 31].
An additional study from Berson et al. in 2004, in 221
patients with RP, showed that combined supplementation
with vitamin A (15000UI/day) and DHA (1200mg/day)
over a 4-year period did not slow the course of RP when
compared to placebo in terms of visual field, visual acuity,
and 30Hz ERG changes [27]. A subsequent subgroup analysis
performed by the same authors showed that, in RP patients
not taking vitamin A therapy before entering the study,
addition of DHA 1200mg/d slowed the decline of visual field
and ERG [26]. Specifically, the mean annual rate of decline
of visual field was not significantly different between the
placebo + vitamin A and DHA + vitamin A groups (30.26 ±
3.92 dB/year versus 39.41 ± 3.76 dB/year, 𝑝 = 0.09), while
patients not taking vitamin A prior to entry to the study
showed significant differences between the placebo + vitamin
A and DHA + vitamin A groups (52.5 ± 5.99 dB/year versus
30.7 ± 6.48 dB/year, 𝑝 = 0.002). Similarly, the percentage of
decline per year of 30Hz ERG amplitudewas not significantly
different for those taking vitamin A prior to entry (9.23% in
placebo + A and 10.57% in DHA + A groups), while patients
not taking vitamin A prior to entry in the study showed
a percentage of decline of 8.05% in the placebo + vitamin
A group and of 12.99% in the DHA + vitamin A group,
which was significant when comparing rates of decline in
both groups of treatment (𝑝 = 0.02) [26].
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3.1.3. Lutein Supplementation. Two RCTs evaluated the
effects of lutein supplementation in patients with RP when
compared to placebo [9, 10]. Bahrami et al. demonstrated a
positive effect of lutein supplementation on preserving visual
filed in a 6-month study on 34 patients with RP. Specifically,
lutein supplementation showed that the mean retinal area
of the central visual field, evaluated by Goldman perimetry,
was 0.018 log higher (𝑝 = 0.038) when compared to placebo
[9]. A later study from Berson et al. evaluated 225 patients
with RP treated with lutein (12mg/day) or placebo in a 4-
year study. All patients were given 15000UI/day of vitamin A.
This study showed no significant difference in visual acuity,
ERG amplitude, and the rate of decline between the lutein
plus vitaminA and control plus vitaminA groups for theHFA
30-2 program. For theHFA60-4 program, a decrease inmean
rate of sensitivity loss was observed in the lutein plus vitamin
A group (𝑝 = 0.05) [9, 10].
3.1.4. Gangliosides Supplementation. One RCT by Newsome
et al. demonstrated no significant effects of gangliosides
administrationwhen compared to placebo on the progression
of RP evaluated by visual field and ERG in a 4-month study
in 32 patients [32].
3.1.5. Beta-Carotene Acid Supplementation. Oral adminis-
tration of 9-cis 𝛽-carotene-rich alga Dunaliella bardawil
(300mg/day) was compared to placebo in a 3-month
crossover study in 29 patients with RP. This study showed
a significant improvement of maximal dark-adapted ERG
b-wave amplitude responses when compared to placebo
(+8.4 𝜇V versus −5.9 𝜇V, resp., 𝑝 = 0.001) with 34.5% of
patients showing an increase ofmore than 10𝜇V for both eyes
in the Dunaliella group. Light-adapted single-flash b-wave
amplitudes were also significantly improved in Dunaliella
group as compared to placebo (+17.8 𝜇V versus −3 𝜇V, resp.,
𝑝 = 0.01) while no significant changes were observed in
visual acuity and visual field assessment [11].
3.1.6. Oral Valproic Acid. One open randomized clinical
trial by Kumar et al. evaluated the effects of 1 year of oral
administration of valproic acid in 30 patients with typical RP.
In this study, only evaluators were masked and 30 patients
were randomized to valproic acid or no treatment. Visual
acuity improved in the treatment group when compared to
baseline and a statistically significant difference with controls
was observed after 1 year (1.3 versus 1.83 LogMar, resp.; 𝑝 ≤
0.01). Multifocal ERG also showed a significant improvement
in the valproic acid group (𝑝 ≤ 0.01) [12].
3.1.7. Brimonidine 0.2% Eye Drops. Topical treatment with
brimonidine tartrate 0.2% (Alphagan; Allergan, Irvine, CA)
was administered to 17 patients with RP for 24/36 months. At
the end of the study therewere no significant benefits in visual
field, visual acuity, and contrast sensitivity when compared to
artificial tears [14].
3.1.8. Ciliary Neurotrophic Factor Intraocular Implants.
Encapsulated cell-ciliary neurotrophic factor intraocular
implants were applied to one randomly selected eye of
133 patients included in two clinical trials on early-stage
(CNTF4) and late-stage (CNTF3) RP. Implants were retained
for 12 or 24 months, with 42 patients receiving low dose
(5 ng/day) implants and 91 patients receiving high dose
implants (20 ng/day). At the end of the study no significant
differences in BCDVA and ERG amplitude were observed,
and the high dose implants induced a significant worsening
in Humphrey visual field sensitivity (CNTF3: −98.4 ±
165.3 high dose versus −14 ± 101.5 sham, 𝑝 = 0.001; CNTF4:
−164.3 ± 114.6 high dose versus−67.1± 104.2 sham,𝑝 < 0.001)
[15].
3.1.9. Oral Nilvadipine. A small nonmasked prospective
study by Nakazawa et al. showed that oral nilvadipine
(4mg/daily) administration in 33 patients for 30–66 months
with RP induced a slower progression of the visual field
deterioration when compared to a control group receiving
tocopherol nicotinate 300mg/day or helenien 15mg/day or
no treatments (mean regression coefficient of theMD slope =
−0.49 ± 0.17 dB/year versus −0.89 ± 0.16 dB/year, resp.; 𝑝 =
0.042) [13].
3.1.10. Hyperbaric Oxygen Delivery. The effects of HBO ther-
apy were evaluated in two studies by Vingolo et al. The
first study reported an improvement of low-noise ERG in
11% and unchanged levels in 89% of patients in the HBO
treatment group, while 62% of patients in the control group
showed worsening of ERG and 38% remained unchanged
with a significant difference between groups (𝑝 < 0.001) [6].
The other study compared HBO to vitamin A treatment and
showed that HBO group had a slower decline in visual func-
tion, a higher percentage of visual field stabilization, and an
improvement of low-noise ERG b-wave amplitude. However,
in this study the dose regimen of the control group (vitamin
A group) was not specified, the dropouts were not described,
and the ERG instrument was changed after 3 years [5].
4. Discussion
Nineteen RCTs included in this review evaluated the effects
of medical treatments on the progression of RP, including
vitamins A and E, DHA, lutein, gangliosides’ supplementa-
tion, HBO delivery, topical brimonidine tartrate treatment,
intraocular CNTF release, oral nilvadipine, beta-carotene,
and oral valproic acid. Among treatments evaluated in this
systematic review, long term vitamin A supplementation
showed a good short and long term safety profile but poor
significant clinical result with the only significant effect being
a slower rate of decline of ERG amplitude [28, 33, 35]. All the
RCTs evaluating the efficacy and safety of DHA treatment
compared to placebo or to vitamin A failed to demonstrate
a beneficial effect of DHA supplementation, despite the good
safety profile [26, 27, 29–31, 36].The only beneficial effect was
described by Berson et al. in a subgroup analysis, showing
that patients with RP beginning vitamin A therapy plus DHA
showed a better clinical outcome of the disease at 2 years
[27]. Although a clear benefit on outcomes that would be
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clinically relevant for patients, such as visual acuity or visual
field amplitude, has not been achieved, based on the results of
all these studies, the evidence supports the supplementation
of adults with early or middle stages of RP with 15000 IU of
oral vitamin A palmitate every day, while supplementation
with high dose vitamin E should be avoided [1, 8, 33, 35].
The encouraging results on the use of lutein supplementation
in patients with RP obtained by Bahrami et al. were not
confirmed by the subsequent RCT by Berson et al. that failed
to demonstrate beneficial effects of lutein supplementation
in terms of visual acuity and visual field [9, 10]. Other
encouraging results come from small studies on 9-cis 𝛽-
carotene-rich algaDunaliella bardawil supplementation, oral
valproic acid, and oral nilvadipine, which demonstrated to
slow the decline of clinical outcomes in patients with RP
[11–13]. However, these data should be confirmed by further
larger, double-masked, controlled studies. The other medical
treatments, including gangliosides’ supplementation, topical
brimonidine tartrate 0.2%, and intravitreal CNTF delivery,
showed no beneficial effects on RP progression and clinical
outcomes [14, 15, 32]. The latter even induced a worsening in
visual field sensitivity when administered at higher doses [15].
Two RCTs by Vingolo et al. showed a significant improve-
ment of low-noise ERG in patients with RP treated withHBO
as compared to control untreated group [6]. In their later
study, a slower progression in HBO group was also reported
[5]. However, the conclusions of the authors are not definitive
as they are not supported by data due to inappropriate
statistical analysis and poor study design.
Nevertheless, we were unable to draw any conclusions at
this time regarding the applicability or otherwise of the cur-
rently available medical interventions for RP because of the
general paucity of evidence from the limited number of RCTs
available and because of the differences between studies (e.g.,
different instruments and different outcome measures) that
made it impossible to compare statistical data from different
studies. Outcome assessment wasmostly performed by visual
acuity, visual field, or ERG evaluations; however, different
instruments or different outcome measures were used for the
same variable in different studies. For example, visual field
was a common outcome assessed by Goldman perimetry or
Humphrey visual field; however, while most of the studies
using Goldman perimetry evaluated the visual field area, the
studies using HFA evaluated the mean deviation or the total
point score from different programs such as 10-2, 30-2, or
60-4. More standardized outcome measures to be used in
RCT evaluation in RP patients should be assessed in the
future, to make results reproducible and comparable. Owing
to different formats of outcome reporting (e.g., mean rate
of decline versus mean observed changes and continuous
versus dichotomous data), different kinds of effect sizes had
to be used, rendering both pooling and comparing of findings
difficult.
Further RCTs with more standardized outcomemeasures
and reporting are needed to definitely demonstrate the
efficacy of the proposed therapeutic interventions and novel
therapeutic agents aimed at improving visual function in
patients with RP are highly sought after.
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